In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies
ABSTRACT: Equid alphaherpesvirus type 1 (EHV-1) is distributed worldwide and is a major agent of abortion, respiratory and neurological disease in horses. No specific treatment is available for EHV-1 infection, yet the potential of antiviral therapy has been explored. In this study we investigated...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade Federal de Santa Maria
2018-12-01
|
| Series: | Ciência Rural |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782018001200450&lng=en&tlng=en |
| _version_ | 1811215369426173952 |
|---|---|
| author | Amanda Lovato de Oliveira Juliana Felipetto Cargnelutti Ana Paula Gnocato Mortari Eduardo Furtado Flores Rudi Weiblen |
| author_facet | Amanda Lovato de Oliveira Juliana Felipetto Cargnelutti Ana Paula Gnocato Mortari Eduardo Furtado Flores Rudi Weiblen |
| author_sort | Amanda Lovato de Oliveira |
| collection | DOAJ |
| description | ABSTRACT: Equid alphaherpesvirus type 1 (EHV-1) is distributed worldwide and is a major agent of abortion, respiratory and neurological disease in horses. No specific treatment is available for EHV-1 infection, yet the potential of antiviral therapy has been explored. In this study we investigated the in vitro activity of Acyclovir, Ganciclovir, Foscarnet, Famciclovir, Vidarabina and Cidofovir against EHV-1. For this, the MTT test was performed, in which all the tested drugs showed no toxicity up to 200μg/mL. Subsequently, different drug concentrations were submitted to viral plaque reduction assays in cell culture. The selectivity index (SI) of the compounds was determined using the cytotoxic concentration for 50% of cells (CC50), obtained by MTT, and effective drug concentration to inhibit by 50% the number of viral plaques (EC50). Ganciclovir (SI: 490; EC50: 1.9 μg/mL) was the most efficient and safest drug against EHV-1, followed by Cidofovir (SI: 150, EC50: 5.7μg/mL), Acyclovir (SI: 37.4, EC50: 22.2μg/mL), Famciclovir (SI: 25.1, EC50: 24.5μg/mL), Vidarabine (SI: 12.2, EC50: 40.9μg/mL) and Foscarnet (SI: 6.9, EC50: 49.5 μg/mL), respectively. These results indicated that Ganciclovir (followed by Cidofovir), is a promising candidate for use in in vivo experiments. |
| first_indexed | 2024-04-12T06:21:35Z |
| format | Article |
| id | doaj.art-9a32a45cfa364b53bbc3b798d7b9a87f |
| institution | Directory Open Access Journal |
| issn | 1678-4596 |
| language | English |
| last_indexed | 2024-04-12T06:21:35Z |
| publishDate | 2018-12-01 |
| publisher | Universidade Federal de Santa Maria |
| record_format | Article |
| series | Ciência Rural |
| spelling | doaj.art-9a32a45cfa364b53bbc3b798d7b9a87f2022-12-22T03:44:17ZengUniversidade Federal de Santa MariaCiência Rural1678-45962018-12-01481210.1590/0103-8478cr20180085S0103-84782018001200450In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studiesAmanda Lovato de OliveiraJuliana Felipetto CargneluttiAna Paula Gnocato MortariEduardo Furtado FloresRudi WeiblenABSTRACT: Equid alphaherpesvirus type 1 (EHV-1) is distributed worldwide and is a major agent of abortion, respiratory and neurological disease in horses. No specific treatment is available for EHV-1 infection, yet the potential of antiviral therapy has been explored. In this study we investigated the in vitro activity of Acyclovir, Ganciclovir, Foscarnet, Famciclovir, Vidarabina and Cidofovir against EHV-1. For this, the MTT test was performed, in which all the tested drugs showed no toxicity up to 200μg/mL. Subsequently, different drug concentrations were submitted to viral plaque reduction assays in cell culture. The selectivity index (SI) of the compounds was determined using the cytotoxic concentration for 50% of cells (CC50), obtained by MTT, and effective drug concentration to inhibit by 50% the number of viral plaques (EC50). Ganciclovir (SI: 490; EC50: 1.9 μg/mL) was the most efficient and safest drug against EHV-1, followed by Cidofovir (SI: 150, EC50: 5.7μg/mL), Acyclovir (SI: 37.4, EC50: 22.2μg/mL), Famciclovir (SI: 25.1, EC50: 24.5μg/mL), Vidarabine (SI: 12.2, EC50: 40.9μg/mL) and Foscarnet (SI: 6.9, EC50: 49.5 μg/mL), respectively. These results indicated that Ganciclovir (followed by Cidofovir), is a promising candidate for use in in vivo experiments.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782018001200450&lng=en&tlng=enEHV-1plaque assayAcyclovirGanciclovirFoscarnetFamciclovirVidarabineCidofovir |
| spellingShingle | Amanda Lovato de Oliveira Juliana Felipetto Cargnelutti Ana Paula Gnocato Mortari Eduardo Furtado Flores Rudi Weiblen In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies Ciência Rural EHV-1 plaque assay Acyclovir Ganciclovir Foscarnet Famciclovir Vidarabine Cidofovir |
| title | In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies |
| title_full | In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies |
| title_fullStr | In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies |
| title_full_unstemmed | In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies |
| title_short | In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies |
| title_sort | in vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies |
| topic | EHV-1 plaque assay Acyclovir Ganciclovir Foscarnet Famciclovir Vidarabine Cidofovir |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-84782018001200450&lng=en&tlng=en |
| work_keys_str_mv | AT amandalovatodeoliveira invitroactivityofsixantiviraldrugsagainstequidalphaherpesvirustype1indicatesgancicloviraspromisingdrugforinvivostudies AT julianafelipettocargnelutti invitroactivityofsixantiviraldrugsagainstequidalphaherpesvirustype1indicatesgancicloviraspromisingdrugforinvivostudies AT anapaulagnocatomortari invitroactivityofsixantiviraldrugsagainstequidalphaherpesvirustype1indicatesgancicloviraspromisingdrugforinvivostudies AT eduardofurtadoflores invitroactivityofsixantiviraldrugsagainstequidalphaherpesvirustype1indicatesgancicloviraspromisingdrugforinvivostudies AT rudiweiblen invitroactivityofsixantiviraldrugsagainstequidalphaherpesvirustype1indicatesgancicloviraspromisingdrugforinvivostudies |